Page last updated: 2024-09-05

symmetric dimethylarginine and Arteriosclerosis Obliterans

symmetric dimethylarginine has been researched along with Arteriosclerosis Obliterans in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Guntani, A; Honma, K; Itoh, H; Iwasa, K; Kyuragi, R; Maehara, Y; Matsumoto, T; Ohmine, T; Onohara, T1

Trials

1 trial(s) available for symmetric dimethylarginine and Arteriosclerosis Obliterans

ArticleYear
The efficacy of oral beraprost sodium, a prostaglandin I2 analogue, for treating intermittent claudication in patients with arteriosclerosis obliterans.
    International angiology : a journal of the International Union of Angiology, 2010, Volume: 29, Issue:2 Suppl

    Topics: Administration, Oral; Aged; Ankle Brachial Index; Arginine; Arteriosclerosis Obliterans; Biomarkers; Endothelin-1; Epoprostenol; Exercise Test; Exercise Tolerance; Humans; Intermittent Claudication; Platelet Aggregation Inhibitors; Prospective Studies; Time Factors; Treatment Outcome; Vasodilation; Vasodilator Agents; Walking

2010